IOF Positions and Statements

The impact of interruption of anti-osteoporosis treatment in patients on therapy with bisphosphonates or denosumab is reviewed in a new International Osteoporosis Foundation (IOF) working group paper 'Fracture risk following intermission of osteoporosis therapy' published in the journal Osteoporosis International.* Read more
Advances in the treatment of children and adolescents with cancer have led to substantial improvements in survival, with a 5-year survival rate of childhood cancer close to 80%. Read more
osteoporosis international, scientific peer-reviewed journal
Economic evaluations that compare interventions in terms of costs and outcomes are increasingly used by decision makers, with economic evaluations now playing an increasing role in pricing and reimbursement decisions. Read more
The widely reported message that vitamin D supplements are not needed, stemming from the recent publication by Bolland et al. in the Lancet Diabetes and Endocrinology, has caused much confusion and concern, particularly amongst older patients with osteoporosis. This statement sets out the response from the International Osteoporosis Foundation. Read more
El mensaje ampliamente divulgado de que los suplementos de vitamina D no son necesarios, como resultado de la reciente publicación de Bolland et al. en The Lancet Diabetes and Endocrinology, ha causado mucha confusión y preocupación, especialmente entre los pacientes mayores con osteoporosis. Esta declaración establece la respuesta de la International Osteoporosis Foundation. Read more
algorithm management of fracture risk in osteoporosis
Fragility fractures are a serious yet neglected complication of both type 1 and type 2 diabetes, with increased risk of fragility fractures in people with diabetes extending across the life span. Read more
osteoporosis international, scientific peer-reviewed journal
A new review, endorsed by the International Osteoporosis Foundation (IOF) and the European Society of Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), provides a succinct summary of several failings of the recent guidelines of the American College of Physicians (ACP) on the treatment of low bone density and osteoporosis. Read more
A new expert consensus endorsed by the European Society for Clinical and Economical Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF) has reviewed the benefits and safety of dietary protein for bone health, based on analyses of major research studies. Read more
Experts from the International Osteoporosis Foundation (IOF) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) regret the recent decision by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) to reject the marketing application for abaloparatide, a potential new treatment option... Read more
In a letter published recently in The Lancet, leading experts have drawn attention to potentially harmful guidance resulting from the recent National Institute for Health and Care Excellence (NICE) updated Technology Appraisal on bisphosphonate use in osteoporosis (TA464). Read more

Pages

Subscribe to IOF Positions and Statements